Cancer Stem Cell News Volume 2.14 | Apr 10 2013

    0
    332

    Cancer Stem Cell News 2.14 April 10, 2013
    CANCER_emailBanner
         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

    TOP STORY
    Activation of PI3K/Akt Pathway by CD133-p85 Interaction Promotes Tumorigenic Capacity of Glioma Stem Cells
    Researchers demonstrated that the phosphorylation of tyrosine-828 residue in CD133 C-terminal cytoplasmic domain mediates direct interaction between CD133 and phosphoinositide 3-kinase (PI3K) 85 kDa regulatory subunit (p85), resulting in preferential activation of PI3K/protein kinase B (Akt) pathway in glioma stem cell relative to matched nonstem cell. [Proc Natl Acad Sci USA] Abstract

    Apply Now: Mammary Stem Cells Training Course (June 8-9 2013) in Vancouver, Canada.

    PUBLICATIONS (Ranked by impact factor of the journal)

    MiR145 Targets the SOX9/ADAM17 Axis to Inhibit Tumor Initiating Cells and IL-6-Mediated Paracrine Effects in Head and Neck Cancer
    Researchers report that ALDH1+CD44+ head and neck squamous cell carcinoma (HNC) cells express reduced levels of miR145. SPONGE-mediated inhibition of miR-145 was sufficient to drive tumor-initiating characteristics in non-tumor-initiating cells (TICs)/ ALDH1-CD44-negative HNC cells. [Cancer Res]
    Abstract | Full Article

    Inertial Focusing for Tumor Antigen-Dependent and -Independent Sorting of Rare Circulating Tumor Cells
    Investigators described an inertial focusing-enhanced microfluidic circulating tumor cell (CTC) capture platform, termed “CTC-iChip,” that is capable of sorting rare CTCs from whole blood at 107 cells/s. [Sci Transl Med] Abstract | Press Release

    Photochemical Internalization (PCI) of Immunotoxins Targeting CD133 Is Specific and Highly Potent at Femtomolar Levels in Cells with Cancer Stem Cell Properties
    CD133 is a putative cancer stem cell marker for a number of different cancers and is suggested to be a therapeutic target. Researchers employed PCI, a minimally invasive method for light-controlled, specific delivery of membrane-impermeable macromolecules from endocytic vesicles to the cytosol, to specifically target CD133-positive cancer cells. [J Control Release] Abstract

    TTC5 Is Required to Prevent Apoptosis of Acute Myeloid Leukemia Stem Cells
    Using a screening strategy, researchers identified the tetratricopeptide repeat motif protein, Tetratricopeptide repeat domain 5 (TTC5) as required for the survival of human acute myeloid leukemia cells. [Cell Death Dis] Full Article

    FK506 Binding Protein 51 Positively Regulates Melanoma Stemness and Metastatic Potential
    Researchers hypothesized a role for FK506 binding protein 51 (FKBP51) in melanoma invasive behavior. Their study provides evidence that the genetic programs of cancer stemness and invasiveness overlap in melanoma, and that FKBP51 plays a pivotal role in sustaining such a program. [Cell Death Dis] Full Article

    Proteomic Analysis Reveals that CD147/EMMPRIN Confers Chemoresistance in Cancer Stem Cell-Like Cells
    Investigators presented a systematic analysis of the cell-surface proteome using a cancer stem cell-like cell line derived from MDA-MB453 breast cancer cells which exhibited a CD44+/CD24 phenotype and chemoresistance. [Proteomics] Abstract

    Rapamycin Inhibits FBXW7 Loss-Induced Epithelial-Mesenchymal Transition and Cancer Stem Cell-Like Characteristics in Colorectal Cancer Cells
    The authors explored whether FBXW7 plays any role in metastatic process. They showed that depletion of FBXW7 induces epithelial-mesenchymal transition in human colon cancer cells along with the increase in cell migration and invasion. Moreover, FBXW7 deficiency promotes the generation of colon cancer stem-like cells in tumor-sphere culture. [Biochem Biophys Res Commun] Abstract

    NVP-LDE-225 (Erismodegib) Inhibits Epithelial-Mesenchymal Transition and Human Prostate Cancer Stem Cell Growth in NOD/SCID IL2Rγ Null Mice by Regulating Bmi-1 and MicroRNA-128
    Scientists examined the molecular mechanisms, by which NVP-LDE-225/Erismodegib (smoothened inhibitor) regulates stem cell characteristics and tumor growth in prostate cancer. [Oncogenesis] Full Article

    Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications

    REVIEWS

    PML-Mediated Signaling and Its Role in Cancer Stem Cells
    The authors summarized and discussed the promyelocytic leukemia (PML)-mediated signaling pathways in cancers and their potential roles in regulating cancer stem cells. [Oncogene] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    SCIENCE NEWS
    OncoMed Presents New Data in Six Anti-Cancer Stem Cell Programs
    OncoMed Pharmaceuticals, Inc. summarized new data highlighting the progress of OncoMed’s pipeline of anti-cancer biologics presented in an oral presentation and five posters. [Press release from OncoMed Pharmaceuticals, Inc. discussing research presented at the American Association of Cancer Research (AACR) Annual Meeting 2013, Washington] Press Release

    From Our Sponsor:
    Pluripotent Cell Isolation for Regenerative Medicine – Request a Free Wallchart from Nature.

    INDUSTRY NEWS

    ASH Awards First Bridge Grants to Sustain Critical Hematology Research During Current Period of Funding Restrictions
    The American Society of Hematology (ASH) announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health. [American Society of Hematology] Press Release

    Researchers to Develop Next Generation Immunotherapy for Children with Deadly Solid Tumors
    Researchers at the Children’s Hospital of Philadelphia, the University of Pennsylvania, and the Primary Children’s Medical Center of Salt Lake City received a $550,000 collaborative grant to test next generation T-cell immunotherapy strategies in children with neuroblastoma. The awardees were selected within a rigorous peer-review process through a new initiative called ACT FAST (Adoptive Cell Therapy For Adolescent/pediatric Solid Tumor), which is spearheaded by Solving Kids’ Cancer. [Solving Kids’ Cancer] Press Release

    Stem Cell Therapeutics Completes Trillium Merger and Issues Stock Options
    Stem Cell Therapeutics Corp. announced that it has completed its merger with Trillium Therapeutics Inc. The shareholders of Trillium voted overwhelmingly to support the merger. [Stem Cell Therapeutics Corp.]
    Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    NEW The Jackson Laboratory: Modeling Human Malignancy with Patient-Derived Xenograft Cancer Models
    April 18, 1:00PM (ET in US)
    Webinar

    NEW The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of Drugs, Chemicals, and the Environment
    May 29-31, 2013
    New York, United States

    Visit our
    events page to see a complete list of events in the cancer stem cell community.

    JOB OPPORTUNITIES

    Postdoctoral Scientist (Eli Lilly)

    PhD Studentship Opportunity (University of East Anglia)

    Postdoctoral Fellow – Epigenetics (Structural Genomics Consortium at University of Toronto)

    PhD Student (Universitätsklinikum Carl Gustav Carus)

    PhD Studentship – Signal Transduction and Cancer Research (Department of Medicine, McGill University)

    Faculties in Cancer Biology & Immunotherapy (Huzhou University School of Medicine)

    Postdoctoral Researcher – Pancreatic Cancer (University of Notre Dame, Department of Biological Sciences)

    Postdoctoral Associate (University of California, Berkeley)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us